Blue Jet Healthcare Ltd held its Q2 FY27 earnings call on November 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.
Record Revenue, Fourth Straight Quarter of Sequential Growth
Highest-ever quarterly revenue of ~Rs.376 crore — Q2 FY 2026-2027 revenue from operations grew 28% QoQ, with EBITDA of ~Rs.119 crore up 21% QoQ; the quarter marked the fourth consecutive quarter of sequential growth.
Gross margin at 49%, down 4% QoQ — compression driven by higher raw material prices (reagents, solvents, catalysts) following the West Asia disruption; timing of purchases, inventory consumption and in-transit stock affects when higher costs hit gross margin.
EBITDA at Rs.119 crore (32% of operating revenue), down 1% QoQ — PAT at Rs.103 crore (27% of total income), flat vs Q1 FY 2026-2027.
H1 FY 2026-2027 revenue at Rs.669 crore, up 29% YoY — growth driven 47% by contrast media and 19% by PI API, with artificial sweetener degrowing 2%; H1 gross margin at 51%, down 3% vs H1 FY 2025-2026.
H1 EBITDA at Rs.217 crore (32%), down 2% YoY — PAT at Rs.181 crore (27% of total income), down 1% YoY; marginal margin reduction attributed to headcount additions and certain logistics costs.
Q2 QoQ segment split — contrast media grew 25% and PI API grew 52% QoQ, while artificial sweetener degrew 30%.
CFO Ganesh Karupanil attributed margin compression to the West Asia crisis — which drove price increases across the board in raw materials, reagents and solvents; an industry-wide impact affecting most pharma companies, beyond the company's control.
As a CDMO, the company cannot pass on 100% of reagent and solvent cost inflation — management has begun discussions with customers on how much it can absorb versus pass through, and expects a positive impact in the coming quarters.
Price increases with certain select customers come into force from Q3 FY 2026-2027 — being reviewed contract-by-contract; timing differences can pressure gross margin before revised pricing takes effect.
On whether Q2 FY 2026-2027 gross margins can serve as a base — the CFO declined to make a guesstimate on crude price direction, noting many chemicals and solvents are crude-linked; if crude remains at current levels, Q2 FY 2026-2027 gross margin should be a reasonable estimate.
Contrast Media and PI API Momentum; Sweeteners Lag
Contrast media sequential uptick of ~Rs.50 crore (subsequently referenced as Rs.30 crore) — MD Shiven Arora described the segment as "quite stable" with good momentum; management did not explicitly confirm whether the uptick reflected the deferred revenue reversal flagged in Q1 FY 2026-2027 versus incremental molecule contribution.
PI API growth led by existing portfolio plus a new molecule — management declined product-level numbers citing confidentiality covenants, but pointed to cardiovascular, oncology and CNS as categories picking up "extremely well"; COO VK Singh confirmed Q2 FY 2026-2027 oncology/CNS supplies were commercial quantities, not validation batches.
Contrast media revenue flat-to-declined at ~$55 million annually in constant currency over the trailing three years — per JP Morgan's Bansi Desai; management responded there is no volume degrowth, with only a "very small" volume-discount impact, and noted unit costs vary widely across the 4-5 products in the category (one at X value, another at 3X).
MD Shiven Arora affirmed existing contrast media products should grow at least in line with end-market growth for those molecules — with newer launches and forward integration adding to that growth (no specific timeframe given).
Artificial sweetener volumes flat over the last 2-3 years — flagged by analyst Ravi Purohit; management attributed Q2 FY 2026-2027 growth to "a combination of both" existing portfolio and new products, but declined granular product-level breakdowns.
Mahad On Track; Vizag Phase 1 at ~Rs.1,000 Crore
Mahad Unit 3 on track to go on stream in H2 FY 2026-2027 — cumulative capex of ~Rs.250 crore incurred to date (as of Q2 FY 2026-2027); the contrast media KSM facility will enable complete backward integration across the relevant part of the contrast media value chain.
Vizag Units 5 & 6: ~100 acres secured, Phase 1 capex of about Rs.1,000 crore (period unspecified) — Phase 1 to include contrast media, pharmaceutical intermediates, peptide fragments, high-intensity sweeteners and multipurpose blocks; EC and consent-to-establish compliances in place with pre-construction underway.
Vizag sweetener capacity anchored by existing clients with firm commitments — COO VK Singh said the new high-intensity sweetener is a separate product from the one currently produced, one that per management none in India currently manufactures, and expects very low gestation.
Hyderabad R&D center operational — ~50 scientists onboarded, planned to add ~100 fume hoods over two phases (period unspecified); new platforms include flow synthesis, peptides, GLP-related intermediates, biocatalysis, high-potency products and solid-phase chemistry.
Rs.800 crore QIP raise completed — proceeds earmarked for capital expenditure, partly working capital and general corporate purposes; deployment to be phased over the next three years per the offer document.
Two high-conviction lateral entries will come from Vizag Phase 1, which is "some time away" — "not happening tomorrow"; analyst cited prior guidance of launches in FY 2026-2027, but no explicit launch period was given.
Peptide entry via building blocks and fragments, not final API — management views fragments as a space with good volume and opportunity; as of Q2 FY 2026-2027 all peptide fragment supplies are trial quantities, including the fragment supplied for the NC.
R&D capability being set up is first for liquid phase synthesis — per COO VK Singh; current supply and tie-ups with other CDMOs/innovators focus on peptide fragments, with liquid/solid phase synthesis relevant only when condensing chains to form the final peptide.
New contrast media intermediate delivered and validated for an innovator in Q2 FY 2026-2027 — an NCE still in clinical phase; a peptide fragment (supply referenced by analyst Amlan Das as beginning Q4 FY 2026-2027) is also destined for a big innovator and in clinical phase; both described as "very interesting and credible" and late phase.
Two PI API molecules in clinical phases "will take a while" to reach commercial stage — while the CNS and onco products are already commercial and part of the PI vertical; quarter-to-quarter status of clinical-stage molecules does not change.
Management explicitly advised against extrapolating historically high asset turns — calling them too high to maintain, and said it is too premature to comment on peptide asset turns/margin structure.
PAA revenue bulk from commercialized products — COO VK Singh endorsed that the bulk of Q2/H1 FY 2026-2027 revenue comes from commercialized products, with relatively smaller value from incubated (clinical-stage) products; management declined to quantify the split.
Good Visibility, But Management Declines Numeric Guidance
Management declined guidance on a Rs.400 crore quarterly revenue run rate — saying it would be "very hard" to give guidance on sustainability of 5-10% sequential growth over Q3-Q4 FY 2026-2027; MD Shiven Arora added that in the CDMO business it is not possible for anyone to give that type of guidance.
Management expects FY 2026-2027 to be a good year — citing good order visibility in both contrast media and PI, while advising against extrapolating the significant sequential Q2 FY 2026-2027 growth in both businesses.
PI segment has seen sequential ramp-up over the last 3-4 quarters, expected to continue — MD Shiven Arora pushed back on the volatility characterization, citing unusually strong visibility for a CDMO given the company's position with the innovator; CFO Ganesh Karupanil declined to confirm H1 FY 2026-2027 as an indication of pharma API growth.
Iodinated contrast media shipment start unconfirmed — on whether iodinated PBS shipments have started, Shiven Arora said it "would be hard to confirm or deny," though the indicated project and past executions "are all intact" with some volume growth expected going forward.
Capacity expansion committed for FY 2026-2027 is "completely on track" — execution on schedule as of Q2 FY 2026-2027; management said major growth going forward will come from the new capacities being added, with the long-term objective of building a globally competitive CDMO platform "over the coming decade."
Post-iodination forward integration expected to deliver a significant jump in revenue realization — per COO VK Singh, each forward integration step historically delivers a step jump in realization and margins; magnitude to be quantified once the step commences — no figure or timeline provided.
Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.
Powered by Cofacto — AI research platform for Indian stocks, every claim cited from primary filings